Intraoperative ketorolac and bleeding after laparoscopic Roux-en-Y gastric by-pass surgery

Area of Science:

• Surgical outcomes
• Pharmacology
• Patient safety

Background:

• Non-steroidal anti-inflammatory drugs (NSAIDs) like ketorolac are used for postoperative pain management.
• NSAIDs are associated with an increased risk of bleeding.
• The safety of intraoperative ketorolac in laparoscopic Roux-en-Y gastric bypass (RYGB) is under investigation.

Purpose of the Study:

• To investigate the association between intraoperative ketorolac administration and postoperative bleeding after laparoscopic RYGB.
• To assess bleeding by measuring hemoglobin reduction and the need for blood transfusions.

Main Methods:

• Retrospective review of patients undergoing laparoscopic RYGB between January 1st and March 1st, 2010.
• Data collected included hemoglobin levels, surgery duration, fluid management, and transfusion requirements.
• Patients were divided into two groups: those who received intraoperative ketorolac and those who did not.

Main Results:

• A total of 162 patients were included; 47 received intraoperative ketorolac, and 115 did not.
• Patients receiving ketorolac showed a significantly higher reduction in hemoglobin levels (-11.3% vs. -8.4%, p=0.018).
• There was no statistically significant difference in transfusion requirements between the groups (2/47 vs. 0/115, p=0.08).

Conclusions:

• Intraoperative ketorolac administration may be associated with increased postoperative hemorrhage after laparoscopic RYGB.
• Further research is warranted to confirm these findings and evaluate alternative pain management strategies.